Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1427)	6/4/2003 4:25:41 PM
From: Micawber	Read Replies (1) \| Respond to of 1475

Anybody remember what they paid for Eligix? Not that it matters, now that they got a whole $450,000 for it. BioTransplant Enters Into Agreement to Sell The Eligix(TM) HDM Cell Separation System to Miltenyi Biotec GmbH Wednesday June 4, 4:01 pm ET - Sale Subject to Bankruptcy Court Approval - MEDFORD, Mass., June 4 /PRNewswire-FirstCall/-- BioTransplant, Inc. (OTC Bulletin Board: BTRNQ.OB - News) today announced that it has entered into an agreement with Miltenyi Biotec GmbH for the sale of its Eligix(TM) HDM Cell Separation System. In connection with this transaction, Miltenyi has agreed to acquire all intellectual property and physical assets associated with the Eligix business in exchange for an upfront payment of $450,000 and royalties of 4-10% of future sales. The Eligix(TM) HDM Cell Separation Systems use monoclonal antibodies to remove unwanted cells from bone marrow, peripheral blood stem cell and donor leukocyte grafts used in transplant procedures. As previously announced, on February 27, 2003, the Company and Eligix, Inc., its wholly-owned subsidiary, filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court in Boston Massachusetts. The sale of the Eligix assets is subject to approval by the bankruptcy court. "We are pleased to enter into this agreement with Miltenyi, which, if approved by the Court, will provide us with both near term capital and potential down-stream royalty income," stated Donald B. Hawthorne, President and Chief Executive Officer of BioTransplant

To: Icebrg who wrote (1427)	6/6/2003 9:08:31 AM
From: Icebrg	Read Replies (1) \| Respond to of 1475

BioTransplant Reports Advances In Xenotransplantation Friday June 6, 9:00 am ET [We already knew that. But it is nice to see that Immerge might still represent some value to BioTransplant. I have been afraid, that when the current agreement period ends in December, BioTransplant will not be able to carry on with this partnership. The chance that Novartis will continue to offer BTRN a free ride should be rather slim). MEDFORD, Mass., June 6 /PRNewswire-FirstCall/ -- BioTransplant, Inc. (OTC Bulletin Board: BTRNQ.OB - News) today announced that scientists from Immerge BioTherapeutics, the Company's joint venture with Novartis Pharma AG, have recently reported results from two studies highlighting advances in xenotransplantation. In one study, Immerge researchers have reversed insulin dependency in diabetic non-human primates through the transplantation of porcine islet cells. In another study, scientists identified the receptors for Porcine Endogenous Retrovirus (PERV), a virus that has shown the ability to infect some human cells in vitro. "These promising studies reflect the significant achievements Immerge has made in the field of xenotransplantation research," stated Donald B. Hawthorne, President and Chief Executive Officer of BioTransplant. "The diabetic primate data underscore the potential applications for xenotransplantation, and the identification of PERV receptors is an important step forward in our efforts to develop xenotransplantation as a safe therapeutic option for humans." At the American Transplant Congress 2003 meeting, researchers from Immerge BioTherapeutics, the Diabetes Institute for Immunology and Transplantation, and the Department of Surgery at the University of Minnesota presented data showing reversal of diabetes in monkeys for more than 70 days after transplantation with porcine islet cells. In this study, diabetic cynomolgus monkeys were transplanted with islets purified from the pancreas of adult pigs or miniature swine. The subjects were then treated with an immunosuppressive cocktail, including induction and maintenance therapy. All animals became insulin independent and reached normal glucose levels in the period after transplantation. A number of animals were insulin-free for up to 70 days after transplantation. None of the animals showed evidence of antibody-mediated rejection. Immerge also announced the identification of the key molecule responsible for Porcine Endogenous Retrovirus (PERV) Infection in the May 27, 2003 edition of The Proceedings of the National Academy of Sciences. Immerge scientists, together with the academic groups of Professors Robin Weiss, University College, London, and Daniel Salomon, The Scripps Research Institute have identified the receptors that are used by PERV in order to enter and infect a cell. This study may allow scientists to begin to develop a strategy to prevent PERV replication. About Immerge BioTherapeutics Immerge BioTherapeutics was formed on September 26, 2000 as a joint venture between Novartis Pharma AG and BioTransplant focused on developing therapeutic applications for xenotransplantation. Both Novartis and BioTransplant have contributed all of their propriety technology in xenotransplantation to the joint venture.